The role of the unique T-cell population, natural killer T (NKT) cells, which have similar functions to NK cells in pancreatic cancer (PC), is not yet evaluated. To address the regulatory roles of NKT cells on tumour progression through tumour-associated macrophages (TAM) and their production of microsomal prostaglandin E synthase-1 (mPGES-1) and 5-lipoxygenase 
Introduction
Pancreatic cancer (PC) is highly lethal. It is difficult to diagnose early, and diagnosis is often made late in the disease course. In 2017, about 53 670 new cases and about 43 090 deaths are estimated to occur in the USA. 1 Even for surgically resectable, and therefore potentially curable, tumours, the risk of cancer recurrence and subsequent death remains high. It is well established that K-ras mutations are commonly (~90-95%) found in human PC. In spite of good progress in our understanding of the molecular aetiology of PC, we still lack significant information regarding the aggressive nature of PC progression and the reason for the poor survival of patients with PC. Recent evidence indicates that inflammation and immune cells in the tumour microenvironment play major roles in PC development and progression. 2 Inverse associations between the numbers and functional activities of immune cells in patients with aggressive cancers suggest that these cells play important roles in anti-tumour immune responses, and that tumour escape from these cells may result in disease progression. It is a well-accepted 
I M M U N O L O G Y O R I G I N A L A R T I C L E
phenomenon that cancer arises from regions of chronic inflammation. In addition, to the oncogenic changes that contribute to cancer development, inflammatory cells, secretory molecules, and cytokines within established tumours can contribute to cancer cell survival and tumour development, growth and progression.
The roles of innate immune natural killer (NK) and natural killer T (NKT) cells in eliminating cancer cells are not fully understood. Recent studies have determined that NK cells and a unique subpopulation of T cells called NKT cells provide an immune surveillance function and play an important role in innate immunity. NKT cells are hypothesized to be deregulated in pancreatic tumour progression and contribute to aggressive tumour growth. Whether genetic loss of NKT cells will enhance or decrease pancreatic tumour progression in a human mimic model is not yet evaluated. How NKT cells regulate the inflammatory environment during pancreatic tumorigenesis is still unclear. NKT cells are reported to decrease monocyte number in neuroblastoma using NOD/SCID mice. 3 However, particularly with regard to how tumour-associated macrophages (TAMs) evade the inhibitory activities of NKT cells in PC are not studied.
We hypothesize based on available literature that NKT cells regulate pro-inflammatory responses by inhibiting TAMs, which may impede tumour growth. The literature suggests that TAM-mediated inflammation occurs through microsomal prostaglandin E synthase-1 (mPGES-1) and plays an essential role in tumour progression. 4, 5 We and others have reported increased expression of mPGES-1 in colon and pancreatic cancers. [4] [5] [6] [7] [8] During inflammation, prostaglandin E 2 (PGE 2 ) and leukotrienes are produced from the metabolism of arachidonic acid by subsequent actions of the inducible enzymes cyclo-oxygenase-2, mPGES-1 and 5-lipoxygenase (5-LOX). PGE 2 exerts antiinflammatory effects and leukotrienes drive inflammation. These two are the potent inflammatory eicosanoids associated with signalling and immunosuppression reactions in cancers. Enhanced PGE 2 and leukotriene synthesis, linked to immunosuppression, has been documented in many human cancers. [9] [10] [11] Several secreted factors, such as PGE 2 and leukotrienes, are known to induce immunosuppression in the tumour microenvironment. As such, no reports are available on whether NKT cells regulate mPGEs-1. However, much is unexplored regarding the involvement of mPGES-1-mediated inflammatory signalling and the immune response remains to be clarified.
We evaluated the roles of NKT cells in pancreatic carcinogenesis by crossing the KPT model (p48
Cre/+ -LSL-Kras G12D/+ ) with CD1-deficient (CD1d À/À ) mice that do not produce type I NKT (invariant or iNKT) or type II NKT (variant or vNKT) cells. The development of immunopreventive or immunotherapeutic strategies is highly dependent on comprehending the NKT-TAM interaction in the tumour microenvironment. NKT cells are immune effector cells, which are responsible for specifically identifying and negatively regulating TAMs. NKT cells are the immune effector cells that may specifically recognize and negatively regulate TAMs.
In the present study, we tested the hypothesis that pancreatic tumour progression is affected by NKT cell regulation of tumour-infiltrating macrophage cells and in turn production of mPGES-1 and 5-LOX. Specifically, our results indicate that tumour progression in the pancreas is highly dependent on the NKT cells and NKT cell-regulated 5-LOX expression and mPGES-1 in M2-type TAMs.
Materials and methods

Mice, diet, handling and drugs
De-identified human tissue samples were kindly provided by the Stephenson Cancer Center Core Facility. Generation of p48
Cre/+ ; LSL-Kras G12D/+ mice expressing the activated Kras G12D oncogene has been described previously.
7
CD1d À/À mice have been described previously, 12 and were housed at University of Oklahoma Health Sciences Center, Oklahoma City, OK. All animal protocols were approved by the Institutional Animal Care and Use Committee of University of Oklahoma Health Sciences Center (OUHSC; Oklahoma City, OK). The research presented in this paper was performed under the approved protocols; 30 ppm YS121 was used to experiments using these mice.
Please see the Supplementary material (Appendix S1) for details.
Breeding and genotyping analysis
LSL-Kras
G12D/+ and p48 Cre/+ mice were maintained in a C57BL/6 heterozygous genetic background and bred. Offspring of activated p48
Cre/+ .LSL-Kras G12D/+ (KPT) and CD1d À/À mice were generated at the required quantities.
KPT-CD1d
À/À were obtained by breeding CD1d À/À mice with KPT mice that have active K-ras and that were deficient in both invariant (i)NKT and variant (v)NKT cells. The genotype of each pup for KPT and CD1d À/À was confirmed by tail DNA extraction and PCR. 7, 12, 13 The loss of CD1d À/À was confirmed by flow cytometry and by tail DNA extraction and PCR in KPT-CD1d À/À mice (see Supplementary material, Fig. S1 ).
Preclinical assays
The animal experiments were performed to understand the role of NKT cells, and the influence of NKT cells on TAMs. In experiments 1 and 2, 6-week-old mice were selected and randomized so that the average body weights in each group were equal (n = 9/6/group). In Experiment 1, to study the role of NKT cells specifically in pancreatic , and KPT mice were used. Animals obtained regular chow until termination of the study. Observation for indications of weight loss or signs of toxicity and other abnormalities was routinely carried out. The mice were weighed once weekly for the first 6 weeks, and then once a month until termination. In experiment 2, to understand the regulatory role of NKT cells on M2-type macrophage mPGES-1 and 5-LOX, KPT-CD1d À/À mice were used. The mice were fed Purina diet for 11 weeks and then AIN-76A experimental diets containing 0 ppm, 30 ppm YS121 until the end of the study. Observation for indications of weight loss or signs of toxicity and other abnormalities was routinely carried out. The mice were weighed once weekly until termination. After 6 weeks on experimental diet, all mice were killed by CO 2 asphyxiation. Pancreata were collected from all experimental groups. Pancreata were then weighed and snap-frozen in liquid nitrogen for further analysis. Collection, fixation and histopathological analysis of pancreata were performed as described earlier. 7, 14 For details please see the Supplementary material (Appendix S1).
Isolation of immune cells and flow cytometric analysis
Pancreata were dissociated with a tumour dissociation kit for isolation of TAMs, NK cells, regulatory T (Treg) cells, and cancer stem cells (CSCs), using a gentleMACS Dissociator and a MACSmix TM Tube Rotator according to the manufacturer's instructions (Miltenyi Biotech, San Diego, CA, USA). The dissociated single-cell suspensions of tumour tissues were treated with Fixation/Permeabilization solution (Biolegend, San Diego, CA, USA.). The fixed/permeabilized single-cell suspensions were labelled with the above-mentioned antibodies for TAMs, NK cells, Treg cells and CSCs, and were analysed on a FACSCalibur. Data were analysed with FlowJo software (FlowJo LLC, Oregon, USA).
Immunohistochemistry and immunohistofluorescence
Immunohistochemistry (IHC) was performed for mPGES-1, CD68, Dclk1, 5-LOX and Lgr5, as reported earlier. 7 Sections of intestinal tissue were processed and incubated for 1 hr at room temperature with primary antibodies for 5-LOX, TAMs (PE-CD68), mPGES-1, Dclk1 and Lgr5. Double immunofluorescent staining for mPGES-1/TAMs, 5-LOX/TAMs and Dclk1/Lgr5 was performed on pancreas sections. The sections were incubated overnight with anti-mPGES-1/anti-5-LOX/anti-Dclk1/ anti-Lgr5 antibodies. The sections were washed three times with PBS for 5 min and were incubated with FITClinked secondary antibody to mPGES-1/5-LOX for 1 hr, along with phycoerythrin-linked anti-CD68 antibody for TAMs. The sections were incubated with FITC-linked secondary antibody to Dclk1 for 1 hr, along with phycoerythrin-linked Lgr5 antibody for CSCs. The sections were washed three times with PBS for 5 min in the dark room, and were incubated with 0Á5 lg/ml 40,6-diamidino-2-phenylindole (DAPI) for 5 min. Sections were rinsed with PBS and were observed for fluorescence under respective filters using an Olympus microscope IX701 (Olympus America, Center Valley, PA, USA.). Digital computer images were recorded with an Olympus DP70 camera. For quantification of Dclk1 cells, Lgr5 cells, NKT cells, 5-LOX, TAMs and mPGES-1, multiple sections and fields of the pancreas tissue were read for positively stained cells as the number of cells per field at 9 400 magnification.
Statistical analysis
All results were expressed as means AE SEM unless otherwise stated. Student's t-test with one-tailed Welch's correction was used to evaluate the significant differences between groups. Differences were considered significant at the P < 0Á05 level. All statistical analysis was performed using GRAPHPAD PRISM Software 5Á1 (GraphPad Software, Inc., San Diego, CA).
Results
Low NKT cells and high mPGES-1and 5-LOX in TAMs from mouse and human pancreatic tumours Fig. S2 ). Double-staining with CD68 and stabilin demonstrated that higher expression of mPGES-1 and 5-LOX occurred in M2 macrophages ( Fig.1c and d ; and see Supplementary material, Fig. S2 ). High mPGES-1 and 5-LOX mRNA expression was observed in mouse pancreatic tumours compared with normal pancreatic tissues (Fig. 1e) . This finding was confirmed by whole genome Illumina sequencing (using t-test, with Benjamini's and Hochberg's corrections) of pancreatic tumours compared with normal pancreas (data not shown). We observed few NKT (Nkp1Á1-positive) cells, in pancreatic tumours from KPT (p48 Cre/+ -LSLKras G12D/+ ) mice, compared with normal pancreatic Phenotypic changes in genetically engineered mice, p48
Cre/+ -LSL-Kras
G12D/+
We observed no phenotypic differences in the three genetically engineered mice used in this study. Furthermore, at the end of the experiments, there were no significant differences in body weight gains between KPT (p48 Cre/+ -LSLKras G12D/+ ) and KPT-CD1d (CD1d
Cre/+ -LSLKras G12D/+ ) mice that were fed the normal or experimental diets (data not shown). None of the animals that were fed the experimental diets exhibited any observable toxicity, defects or gross changes attributable to liver, kidney or lung damage, despite notable differences in the pancreatic weights, as described below. No NKT staining was observed in KPT-CD1d mice (see Supplementary material, Fig. S3 ). Flow cytometry analysis confirmed the loss of CD1d in KPT-CD1d mice (see Supplementary material, Fig. S3 ). The only exception was observable organ-specific (pancreatic) tumour growth in each of the KPT and KPT-CD1d genetically engineered mice, due to activation of K-ras.
Increased PC progression in NKT-deficient KPT-CD1d mice
To further validate the role of NKT cells in pancreatic tumour progression, we generated KPT-CD1d mice, which lack both iNKT and vNKT cells in an activated KPT background. We observed a significant difference (36%, P < 0Á04) in the pancreas weights of KPT-CD1d mice compared with KPT mice (Fig. 2a) . Histological evaluation of Haematoxylin & Eosin-stained figures suggested an increase in pancreatic intraepithelial neoplasia (PanIN) lesions in KPT-CD1d mice compared with KPT mice (Fig. 2b) . The pathologist's quantification of the histology slides revealed a 50% increase in total PanIN lesion formation in the absence of NKT cells in KPT-CD1d mice compared with that found in KPT mice (Fig. 2c) . (Fig. 2d) . The difference in PanIN 1 lesions was two-fold (Fig. 2d) . Importantly, a~43% increase was observed in PanIN3 (carcinoma in situ) lesions in KPT-CD1d mice compared with KPT mice. In addition, the percentage of normal pancreas decreased significantly in KPT-CD1d mice (Fig. 2e) . We did not observe any carcinomas in KPT or KPT-CD1d mice at this age.
Decreased NK cell activity, CD8 cell cytotoxicity, and increased Treg cell and tumour cell proliferation in KPT-CD1d mice
As it is known that NKT cells transactivate NK cell activity and influence adaptive immunity, we analysed the association of NKT loss in the KPT-CD1d mice with altered NK cell activity, CD8 cells cytotoxicity, and Treg cells. We observed that the percentages of active NK cells [Nkp46 and interferon-c (IFN-c); 0Á5400 AE 0Á07, versus 0Á034 AE 0Á008, P < 0Á01; Fig. 2f ] and CD8 (CD8a, CD25 and IFN-c) cytotoxic cells were reduced in KPT-CD1d mice, compared with KPT mice (1Á60 AE 0Á3500 versus 0Á50 AE 0Á2650, not significant; Fig. 2g ). A significant (P < 0Á004) increase in the percentage of Treg cells was also observed in KPT-CD1d mice (38Á00 AE 1Á732; Fig. 2h ), compared with KPT mice (23Á0 AE 1Á719; Fig. 2h ). Furthermore, we observed significant increases in PCNA-(53Á82 AE 4Á684 versus 84Á25 AE 7Á36, P < 0Á008) and Ki67-(66Á32 AE 5Á1 versus 86Á75 AE 5Á33, P < 0Á01) positively stained cells in KPT-CD1d mice compared with KPT mice (Fig. 3a-c) .
Increased expression of mPGES-1/5-LOX in TAMs and cancer stem-like cells in KPT-CD1 mice
The pancreatic tumours from KPT-CD1d mice had higher expression of mPGES-1 (~12%)/5-LOX (~28%) and more TAMs (CD68 positive cells, 106Á8 AE 8Á85 versus 63Á50 AE 3Á61, P < 0Á01) compared with KPT mice (Fig. 4a-f) . Furthermore, the pancreatic tumours analysed using flow cytometry suggested an increased expression of mPGES-1 in cells that were double-positive for CD68 and stabilin (M2-type macrophages) in KPT-CD1d mice compared with KPT mice (Fig. 4g-h ). Also the pancreatic tumours analysed using flow cytometry suggested an increased expression of 5-LOX in cells that were doublepositive for CD68 and stabilin (M2-type macrophages) in KPT-CD1d mice compared with KPT mice (Fig. 5a-f) .
Because the PGE 2 metabolite of mPGES-1 has been shown to enhance cancer cell stemness in tumours, 15, 16 and mPGES-1 is increased in KPT-CD1d mice, we compared the expression of CSCs using markers DCLK1 and LGR5 in pancreatic tumours from KPT-CD1d and KPT mice. Immunohistochemical analysis of the pancreatic tumours showed a similar increase in the number of Dclk1-and Lgr5-positive cells in the KPT-CD1d tumours compared with the KPT tumours (Dclk1-71Á75 AE 5Á250 versus 38Á82 AE 2Á888, P < 0Á002; Lgr5-9Á250 AE 1Á315 versus 5Á070 AE 0Á8895, P < 0Á01, respectively; Fig. 5c-f) . These results suggest that increases in CSCs were associated with an increase in mPGES-1 expression and absence of NKT cells in KPT-CD1d mice.
Pharmacological inhibition of mPGES-1/5-LOX decreased pancreatic tumorigenesis in KPT-CD1d mice
We used a specific mPGES-1/5-LOX inhibitor, YS121, to test whether these enzymes play a role in the reduced pancreatic tumorigenesis observed in KPT-CD1d mice. Histological evaluation of the pancreatic tumours after 6 weeks of YS121 treatment revealed fewer PanIN lesions and most pancreas tissue devoid of PanIN lesions in the treatment group (Fig. 6a and b) . Flow cytometry analysis showed a significant decrease in the percentage of M2 macrophages specifically expressing mPGES-1/5-LOX in pancreatic tumours (10%, P < 0Á04) of KPT-CD1d mice treated with YS121 compared with untreated KPT-CD1d mice (32Á33 AE 6Á386, versus 78 AE 5Á460 P < 0Á01/ 21Á00 AE 1Á528 versus 38 AE 1Á444, P < 0Á002; Fig. 6c and ). PanIN 3 lesions and/or carcinomas in situ were completely suppressed in the YS121-treated mice (Fig. 6e,f) . Up to 92Á5% of the pancreata from KPT-CD1d mice treated with YS121 appeared normal (i.e. free from PanIN lesions), whereas only up to 30% appeared normal in the untreated KPT-CD1d mice (Fig. 6g) . Furthermore, the numbers of CD68-positive macrophage cells were significantly decreased in YS-121-treated pancreata compared with untreated pancreata in KPT-CD1d mice (38Á50 AE 3Á38 versus 10Á25 AE 2Á9, P < 0Á007; Fig. 6h-i) .
mPGES-1 inhibition led to decreased expression of CSCs and proliferation indices in KPT-CD1d mice
As shown in Fig. 7(a and b) when evaluated by IHC and immunohistofluorescence (IHF), pancreatic tissues of YS121-treated KPT-CD1d mice showed significantly reduced (%, 91Á34 AE 3Á672 versus 48Á90 AE 2Á617, P < 0Á001) expression of markers of CSCs compared with KPT mice (Fig. 7a-d (mean AE SEM, 58Á25 AE 5Á154 versus 3Á500 AE 0Á6455, P < 0Á0009). IHF analysis showed that cells that were double-positive for Dclk1 and Lgr5 were also reduced upon treatment with YS121 (mean AE SEM, 6Á500 AE 0Á6455 versus 1Á500 AE 0Á6455, P < 0Á0008). Taken together, these findings ( Fig. 7c and d) suggest that mPGES-1/5-LOX inhibition led to a decrease in the CSCs. Ki67 and PCNA staining was performed on tumour tissues to assess tumour inhibition. Significant inhibition of proliferation markers Ki67 (Fig. 7e, upper panel) and PCNA (Fig. 7f , lower panel) were also observed in the pancreata from YS121-treated mice. Decreased proliferation indices for Ki67 staining (63Á35 AE 3Á897 versus 5Á250 AE 1Á652, P < 0Á0001) and , for PCNA staining (36Á32 AE 3Á581 versus 6Á000 AE 1Á080, P < 0Á002) were observed in pancreatic tumours of YS121-treated mice compared with untreated mice (Fig. 7g and h ).
Pharmacological inhibition of mPGES-1/5-LOX restored NK cell and CD8 + cell cytotoxicity and reduced Treg cells in KPT-CD1d mice Although Nkp46-positive cells were present in the pancreata of control KPT-CD1d mice, these cells were devoid of IFN-c expression, suggesting loss of activity. Suppression of mPGES-1 resulted in active NK cell populations in treated pancreatic tumours (untreated 0Á05133 AE 0Á02467 versus treated 0Á2610 AE 0Á02616, P < 0Á005, Fig. 8a,b) . In further analysis for effects on adaptive immunity, a significant increase in CD8 + cells cytotoxicity (untreated 0Á5700 AE 0Á1060 versus treated 34Á00 AE 5Á292, P < 0Á01; Fig. 8c,d ) and a decrease in the percentage of Treg cells (untreated 40Á48 AE 0Á7157 versus treated 1Á8 AE 0Á2310, P < 0Á0001; Fig. 8e,f) were observed in treated pancreatic tumours, compared with untreated pancreatic tumours.
Discussion
To our knowledge, this is the first study addressing the role of NKT cell-mediated anti-tumour immunity in pancreatic tumorigenesis. Our results demonstrate the presence and absence of NKT cells with pancreatic tumour progression, and provide mechanistic insight into these associations. Human clinical specimens and KPT specimens exhibited lower levels of NKT cells in pancreatic tumours than in normal pancreatic tissue. In addition, the M2-type macrophages within the tumours expressed higher levels of mPGES-1and 5-LOX than did the macrophages in normal tissue. Induction of early anti-tumour immune responses by NK cells and NKT cells has been reported in several studies; more emphasis was given towards increasing NK cell immune responses by using combination immune therapies. [17] [18] [19] [20] [21] [22] KPT-CD1d mice, which produced no NKT cells, exhibited increased pancreatic tumour development and progression and more TAM M2, which expressed higher levels of mPGES1/5-LOX, compared with what was observed in KPT mice. These results indicate that (i) the absence of NKT cells might have led to an increase in macrophages, and (ii) an increase of mPGES-1/5-LOX expression in M2 macrophages. These data suggest that NKT cells inhibit pancreatic tumorigenesis by modulating M2 macrophages and their expression of mPGES-1/5-LOX. To further test this theory, we inhibited mPGES-1/5-LOX in KPT-CD1d mice and analysed PanIN lesion progression. A dramatic decrease in PanIN I and II lesions was observed, with no PanIN III (carcinoma in situ), upon inhibition of mPGES-1/5-LOX. Suggesting that NKT cells possess natural anti-tumour properties -rather than killing tumour cells directly, they modulate non-malignant cells such as TAMs via the inhibition of TAM-specific mPGES-1/5-LOX, which is a critical mechanism for the survival and growth of the neoplastic cells (Fig. 9) . Furthermore, the inhibition of pancreatic tumour progression caused by the mPGES1/5-LOX inhibitor was associated with altered immune cell profiles (increased NK cell and CD8 + cell cytotoxicity and decreased Treg cells) and reduction of tumour cell CSC biomarker expression within the pancreatic tumours. We and others reported that high levels of PGE 2 support the enhancement or protection of CSCs during pancreatic tumorigenesis. In the tumour microenvironment, mPGES-1 in the TAMs is primarily responsible for PGE 2 ; the TAMs appear to protect CSCs from anti-tumour immune cytotoxic cells, so promoting tumour progression and recurrence. 23, 24 It was recently observed that NKT cells control tumour-supportive inflammation by killing M2-like TAMs or by polarizing them to M1 in a xenograft model. 25 The CD1d mouse model used in the present study is devoid of type 1 and 2 NKT cells, because both these cell types are CD1d-restricted. The functions of type I NKT cells were reported to be suppressed by type II NKT cell The protective role of NKT cells in tumour immunosurveillance has been reported in melanomas, fibrosarcomas and in a transgenic prostate cancer mouse model. 13, [27] [28] [29] The NKT cells transactivate NK cells through production of IFN-c. In the present study, YS121 increased IFN-c production by NK cells in KPT, although total IFN-c production in the pancreatic tumours was not significant (data not shown). In addition, we observed tumour-specific activation of CD8a T-cell responses towards proliferating tumour cells. mPGES-1/5-LOX in M2 macrophage inhibition increased CD8a + -CD25 + -IFNc-producing cells and decreased Treg cells. Most inflammatory cells, however, reside in the tumour stroma, and can produce inflammatory eicosanoids, such as PGE 2 , which in turn influence tumour cell proliferation and help the tumour escape from anti-tumour immune responses. It is evident from our results that NKT cells play a regulatory role on other immune cells through mPGES-1/5-LOX in M2. Further in-depth experiments to study how mPGES-1/5-LOX may regulate Treg cell function are warranted. These results suggest that, in a scenario of fewer/less active NKT cells during tumorigenesis, suppression of mPGES-1/5-LOX could enhance antitumour functions in pancreatic carcinogenesis. Hence, the development of agents to enhance NKT cell function or to inhibit mPGES-1 for clinical PC prevention or treatment is warranted.
In conclusion, the present study demonstrates altered pancreatic tumour development and progression in mice with altered immune cell profiles, but within the otherwise isogenic KPT background. The absence of NKT cells was associated with increased pancreatic tumour development and progression. Higher levels of mPGES-1/5-LOX in the TAMs upon the loss of NKT cells appear to contribute to pancreatic tumour progression. in flow cytometry measurements, IHC and IHF; R.R. 
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